160 related articles for article (PubMed ID: 7682054)
21. Blood activation during neonatal extracorporeal life support.
Plötz FB; van Oeveren W; Bartlett RH; Wildevuur CR
J Thorac Cardiovasc Surg; 1993 May; 105(5):823-32. PubMed ID: 7683735
[TBL] [Abstract][Full Text] [Related]
22. Comparison of three dose regimens of aprotinin in infants undergoing the arterial switch operation.
Verma YS; Chauhan S; Bisoi AK; Gharde P; Kiran U; Das SN
Ann Card Anaesth; 2010; 13(2):110-5. PubMed ID: 20442540
[TBL] [Abstract][Full Text] [Related]
23. Low doses of aprotinin in aortocoronary bypass surgery--advantages and disadvantages.
Golański R; Golański J; Chizyński K; Iwaszkiewicz A; Zasłonka J; Pietrucha T; Chrul S; Watała C
Med Sci Monit; 2000; 6(4):722-8. PubMed ID: 11208399
[TBL] [Abstract][Full Text] [Related]
24. Aprotinin has no effect on platelet activation and adhesion during cardiopulmonary bypass.
Wahba A; Black G; Koksch M; Rothe G; Preuner J; Schmitz G; Birnbaum DE
Thromb Haemost; 1996 May; 75(5):844-8. PubMed ID: 8725734
[TBL] [Abstract][Full Text] [Related]
25. Increased anticoagulation during cardiopulmonary bypass by aprotinin.
de Smet AA; Joen MC; van Oeveren W; Roozendaal KJ; Harder MP; Eijsman L; Wildevuur CR
J Thorac Cardiovasc Surg; 1990 Oct; 100(4):520-7. PubMed ID: 1699088
[TBL] [Abstract][Full Text] [Related]
26. Clinical inhibition of the seven-transmembrane thrombin receptor (PAR1) by intravenous aprotinin during cardiothoracic surgery.
Day JR; Punjabi PP; Randi AM; Haskard DO; Landis RC; Taylor KM
Circulation; 2004 Oct; 110(17):2597-600. PubMed ID: 15262827
[TBL] [Abstract][Full Text] [Related]
27. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
Despotis GJ; Joist JH
J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
[TBL] [Abstract][Full Text] [Related]
28. Low-dose and high-dose aprotinin improve hemostasis in coronary operations.
Speekenbrink RG; Wildevuur CR; Sturk A; Eijsman L
J Thorac Cardiovasc Surg; 1996 Aug; 112(2):523-30. PubMed ID: 8751522
[TBL] [Abstract][Full Text] [Related]
29. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass.
van Oeveren W; Jansen NJ; Bidstrup BP; Royston D; Westaby S; Neuhof H; Wildevuur CR
Ann Thorac Surg; 1987 Dec; 44(6):640-5. PubMed ID: 2446574
[TBL] [Abstract][Full Text] [Related]
30. Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass.
Shigeta O; Kojima H; Jikuya T; Terada Y; Atsumi N; Sakakibara Y; Nagasawa T; Mitsui T
Circulation; 1997 Jul; 96(2):569-74. PubMed ID: 9244227
[TBL] [Abstract][Full Text] [Related]
31. Influence of heparin, heparin plus aprotinin and hirudin on contact activation in a cardiopulmonary bypass model.
Wendel HP; Heller W; Gallimore MJ
Immunopharmacology; 1996 May; 32(1-3):57-61. PubMed ID: 8796267
[TBL] [Abstract][Full Text] [Related]
32. Influence of high- and low-dose aprotinin on activation of hemostasis in open heart operations.
Dietrich W; Schöpf K; Spannagl M; Jochum M; Braun SL; Meisner H
Ann Thorac Surg; 1998 Jan; 65(1):70-7; discussion 77-8. PubMed ID: 9456098
[TBL] [Abstract][Full Text] [Related]
33. Effects of aprotinin on anticoagulant monitoring: implications in cardiovascular surgery.
Najman DM; Walenga JM; Fareed J; Pifarré R
Ann Thorac Surg; 1993 Mar; 55(3):662-6. PubMed ID: 7680854
[TBL] [Abstract][Full Text] [Related]
34. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy.
Lu H; Du Buit C; Soria J; Touchot B; Chollet B; Commin PL; Conseiller C; Echter E; Soria C
Thromb Haemost; 1994 Sep; 72(3):438-43. PubMed ID: 7531877
[TBL] [Abstract][Full Text] [Related]
35. "Low-dose" aprotinin modifies hemostasis but not proinflammatory cytokine release.
Ashraf S; Tian Y; Cowan D; Nair U; Chatrath R; Saunders NR; Watterson KG; Martin PG
Ann Thorac Surg; 1997 Jan; 63(1):68-73. PubMed ID: 8993243
[TBL] [Abstract][Full Text] [Related]
36. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass.
Blauhut B; Gross C; Necek S; Doran JE; Späth P; Lundsgaard-Hansen P
J Thorac Cardiovasc Surg; 1991 Jun; 101(6):958-67. PubMed ID: 1710008
[TBL] [Abstract][Full Text] [Related]
37. Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery.
Davis R; Whittington R
Drugs; 1995 Jun; 49(6):954-83. PubMed ID: 7543841
[TBL] [Abstract][Full Text] [Related]
38. Low-dose heparin versus full-dose heparin with high-dose aprotinin during cardiopulmonary bypass. A preliminary report.
von Segesser LK; Garcia E; Turina MI
Tex Heart Inst J; 1993; 20(1):28-32. PubMed ID: 7685221
[TBL] [Abstract][Full Text] [Related]
39. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management.
Koster A; Fischer T; Praus M; Haberzettl H; Kuebler WM; Hetzer R; Kuppe H
Anesthesiology; 2002 Oct; 97(4):837-41. PubMed ID: 12357148
[TBL] [Abstract][Full Text] [Related]
40. Coagulation and fibrinolysis system in aortic surgery under deep hypothermic circulatory arrest with aprotinin: the importance of adequate heparinization.
Okita Y; Takamoto S; Ando M; Morota T; Yamaki F; Matsukawa R; Kawashima Y
Circulation; 1997 Nov; 96(9 Suppl):II-376-81. PubMed ID: 9386127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
